HC Wainwright Issues Negative Forecast for Cibus Earnings

Cibus, Inc. (NASDAQ:CBUS) – Equities researchers at HC Wainwright cut their Q4 2024 earnings estimates for shares of Cibus in a research note issued to investors on Monday, November 11th. HC Wainwright analyst A. Dayal now anticipates that the company will post earnings of ($1.00) per share for the quarter, down from their previous estimate of ($0.96). HC Wainwright currently has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Cibus’ current full-year earnings is ($3.84) per share. HC Wainwright also issued estimates for Cibus’ FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($1.05) EPS.

Several other equities analysts have also recently issued reports on CBUS. Alliance Global Partners reduced their price objective on Cibus from $25.00 to $23.50 and set a “buy” rating for the company in a report on Tuesday, September 24th. Canaccord Genuity Group raised Cibus to a “strong-buy” rating in a research note on Friday, July 19th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price objective on shares of Cibus in a research note on Tuesday, October 22nd.

Cibus Trading Down 7.7 %

CBUS stock opened at $5.31 on Wednesday. Cibus has a 52 week low of $2.86 and a 52 week high of $23.18. The company has a market cap of $122.61 million, a P/E ratio of -0.26 and a beta of 1.79. The company’s 50-day moving average price is $4.06 and its 200 day moving average price is $8.68.

Institutional Investors Weigh In On Cibus

A number of large investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Cibus in the third quarter valued at $33,000. Charles Schwab Investment Management Inc. lifted its holdings in Cibus by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock valued at $161,000 after purchasing an additional 6,276 shares in the last quarter. FineMark National Bank & Trust boosted its stake in shares of Cibus by 24.3% during the 2nd quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock worth $202,000 after purchasing an additional 4,000 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Cibus during the second quarter worth about $214,000. Finally, Rhumbline Advisers acquired a new position in shares of Cibus in the second quarter valued at approximately $221,000. Institutional investors and hedge funds own 33.81% of the company’s stock.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.